The significance of SIRI and SII scores in predicting the effect of omalizumab treatment in patients with severe allergic asthma
Main Article Content
Keywords
asthma control test, severe asthma, Omalizumab, SIRI, SII
Abstract
Objective: To evaluate the role of systemic inflammation response index (SIRI) and systemic immune-inflammation index (SII) biomarkers in predicting the response to omalizumab (OMA) treatment in patients with severe allergic asthma.
Methods: A retrospective analysis was conducted to examine the correlation between the fourth-month treatment responses of patients undergoing OMA therapy for severe allergic asthma and their baseline neutrophil, lymphocyte, monocyte, and platelet values, as well as SIRI and SII scores.
Results: Posttreatment asthma control scores had a positive correlation with baseline SIRI (p = 0.03, r = 0.358), SII (p = 0.04, r = 0.345), and serum neutrophil values (p = 0.01, r = 0.308), and a negative correlation with lymphocyte values (p = 0.00, r = −0.398). Baseline SII showed a negative correlation with posttreatment systemic steroid usage (mg) (p = 0.04, r = −0.247) and the number of exacerbations (p = 0.02, r = −0.269).
Conclusion: SIRI and SII scores hold promise for predicting the success of OMA therapy; however, their utility needs to be validated in larger patient cohorts and further studies.
References
1 Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat. Rev. Immunol. 2018;18(7):454–466. 10.1038/s41577-018-0006-6
2 Global Initiative for Asthma. 2024 GINA Main Report. Global strategy for asthma management and prevention. Accessed on July 12, 2024. Available from: https://ginasthma.org/2024-report/
3 Chung KF, Wenzel SE, Brozek JL. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014;43:343–373. 10.1183/09031936.00202013
4 Nordon C, Grimaldi-Bensouda L, Pribil C. Clinical and economic burden of severe asthma: A French cohort study. Respir. Med. 2018;144:42–49. 10.1016/j.rmed.2018.10.002
5 Sadatsafavi M, Lynd L, Marra C. Direct health care costs associated with asthma in British Columbia. Can. Respir. J. 2010;17:74–80. 10.1155/2010/361071.
6 Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin. Rev. Allergy Immunol. 2018;56:219–233. 10.1007/s12016-018-8712-1
7 Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015:879783. 10.1155/2015/879783
8 Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol. Int. 2019;68:158–66. 10.1016/j.alit.2019.01.004
9 McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am. J. Respir. Crit. Care Med. 2019;199:433–45. 10.1164/rccm.201810-1944CI
10 Manka LA and Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann. Allergy Asthma Immunol. 2018;121:406–13. 10.1016/j.anai.2018.07.033
11 Coşansu NC, Kara RÖ, Yaldiz M, Dikicier BS. New markers to predict the response to omalizumab in chronic spontaneous urticaria. Derm. Ther. 2022;35:15589. 10.1111/dth.15589
12 Uysal MA, Mungan D, Yorgancioglu A, Yildiz F, Akgun M, Gemicioglu B, et al. Turkish asthma control test (TACT) study group. The validation of the Turkish version of asthma control test. Qual. Life Res. 2013 Sep;22(7):1773–9. 10.1007/s11136-012-0309-1. Epub 2012 Nov 10. Erratum In: Qual. Life Res. 2013 Sep;22(7):1781–2.
13 Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, et al. Exploring definitions and predictors of response to biologics for severe asthma. J. Allergy Clin. Immunol. Pract. 2024 Sep 12(9):2347–2361. 10.1016/j.jaip.2024.05.016
14 Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al. SoMOSA study team and the U-BIOPRED study team. Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: Results of the SoMOSA study. Am. J. Respir. Crit. Care Med. 2024 Aug 1;210(3):288–297. 10.1164/rccm.202310-1730OC
15 Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: A 20-year follow-up cohort study of 42,875 US Adults. J. Clin. Med. 2023 Jan 31;12(3):1128. 10.3390/jcm12031128
16 Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016 Jul 15;122(14):2158–67. 10.1002/cncr.30057
17 Liang Z, Liu L, Zhao H, Xia Y, Zhang W, Ye Y, et al. A systemic inflammatory endotype of asthma with more severe disease identified by unbiased clustering of the serum cytokine profile. Medicine (Baltimore). 2016 Jun;95(25):e3774. 10.1097/MD.0000000000003774
18 Monteseirín J. Neutrophils and asthma. J. Investig. Allergol. Clin. Immunol. 2009; 19:340–54.
19 Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30:538–46. 10.1016/j.it.2009.06.006
20 Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. 1993 Sep 148(3):713–9. 10.1164/ajrccm/148.3.713
21 Gane JM, Stockley RA, Sapey E. TNF-α autocrine feedback loops in human monocytes: The pro-and anti-inflammatory roles of the TNF-α receptors support the concept of selective TNFR1 blockade in vivo. J. Immunol. Res. 2016;1079851. 10.1155/2016/1079851
22 Eguíluz-Gracia I, Malmstrom K, Dheyauldeen SA, Lohi J, Sajantila A, Aaløkken R, et al. Monocytes accumulate in the airways of children with fatal asthma. Clin. Exp. Allergy. 2018; 48:1631–9. 10.1111/cea.13265
23 Schuijs MJ, Willart MA, Hammad H, Lambrecht BN. Cytokine targets in airway inflammation. Curr Opin Pharmacol. 2013;13:351–61. 10.1016/j.coph.2013.03.013
24 Olcay I, Yardımcı S, Delibaşı T, Müftüoğlu O. Platelet functions in patients with allergic asthma. Turk. J. Haematol. 2001 Dec 5;18(4):245–50.
25 Corlateanu A, Stratan I, Covantev S, Botnaru V, Corlateanu O, Siafakas N. Asthma and stroke: A narrative review. Asthma. Res. Pract. 2021;7:3. 10.1186/s40733-021-00069-x
26 Mizuno M, Adachi M, Maruyama S, Suganuma T, Okada T, Takahashi T. The changes in plasma beta-thromboglobulin (Beta-TG), platelet factor 4 (PF4) and thromboxane B2 (TXB2) after a bronchial provocation test (BPT) with house dust (HD) allergen. Arerugi. 1991;40(5):500–5.
27 Idzko M, Pitchford S, Page C. Role of platelets in allergic airway inflammation. J. Allergy Clin. Immunol. 2015;135(6):1416–23. 10.1016/j.jaci.2015.04.028
28 Cheng W, Bu X, Xu C, Wen G, Kong F, Pan H, et al. Higher systemic immune-inflammation index and systemic inflammation response index levels are associated with stroke prevalence in the asthmatic population: A cross-sectional analysis of the NHANES 1999-2018. Front. Immunol. 2023 Aug 4;14:1191130. 10.3389/fimmu.2023.1191130
29 Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–e503. 10.1016/S1470-2045(14)70263-3
30 Erdogan T. Role of systemic immune-inflammation index in asthma and NSAID-exacerbated respiratory disease. Clin. Respir. J. 2021;15:400–5. 10.1111/crj.13314
31 Tarkowski B, Ławniczak J, Tomaszewska K, Kurowski M, Zalewska-Janowska A. Chronic urticaria treatment with omalizumab-verification of NLR, PLR, SIRI and SII as biomarkers and predictors of treatment efficacy. J. Clin. Med. 2023 Apr 1;12(7):2639. 10.3390/jcm12072639
2 Global Initiative for Asthma. 2024 GINA Main Report. Global strategy for asthma management and prevention. Accessed on July 12, 2024. Available from: https://ginasthma.org/2024-report/
3 Chung KF, Wenzel SE, Brozek JL. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur. Respir. J. 2014;43:343–373. 10.1183/09031936.00202013
4 Nordon C, Grimaldi-Bensouda L, Pribil C. Clinical and economic burden of severe asthma: A French cohort study. Respir. Med. 2018;144:42–49. 10.1016/j.rmed.2018.10.002
5 Sadatsafavi M, Lynd L, Marra C. Direct health care costs associated with asthma in British Columbia. Can. Respir. J. 2010;17:74–80. 10.1155/2010/361071.
6 Kuruvilla ME, Lee FEH, Lee GB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin. Rev. Allergy Immunol. 2018;56:219–233. 10.1007/s12016-018-8712-1
7 Pelaia G, Vatrella A, Busceti MT, Gallelli L, Calabrese C, Terracciano R, et al. Cellular mechanisms underlying eosinophilic and neutrophilic airway inflammation in asthma. Mediators Inflamm. 2015:879783. 10.1155/2015/879783
8 Busse WW. Biological treatments for severe asthma: A major advance in asthma care. Allergol. Int. 2019;68:158–66. 10.1016/j.alit.2019.01.004
9 McGregor MC, Krings JG, Nair P, Castro M. Role of biologics in asthma. Am. J. Respir. Crit. Care Med. 2019;199:433–45. 10.1164/rccm.201810-1944CI
10 Manka LA and Wechsler ME. Selecting the right biologic for your patients with severe asthma. Ann. Allergy Asthma Immunol. 2018;121:406–13. 10.1016/j.anai.2018.07.033
11 Coşansu NC, Kara RÖ, Yaldiz M, Dikicier BS. New markers to predict the response to omalizumab in chronic spontaneous urticaria. Derm. Ther. 2022;35:15589. 10.1111/dth.15589
12 Uysal MA, Mungan D, Yorgancioglu A, Yildiz F, Akgun M, Gemicioglu B, et al. Turkish asthma control test (TACT) study group. The validation of the Turkish version of asthma control test. Qual. Life Res. 2013 Sep;22(7):1773–9. 10.1007/s11136-012-0309-1. Epub 2012 Nov 10. Erratum In: Qual. Life Res. 2013 Sep;22(7):1781–2.
13 Scelo G, Tran TN, Le TT, Fagerås M, Dorscheid D, Busby J, et al. Exploring definitions and predictors of response to biologics for severe asthma. J. Allergy Clin. Immunol. Pract. 2024 Sep 12(9):2347–2361. 10.1016/j.jaip.2024.05.016
14 Djukanović R, Brinkman P, Kolmert J, Gomez C, Schofield J, Brandsma J, et al. SoMOSA study team and the U-BIOPRED study team. Biomarker predictors of clinical efficacy of the anti-IgE biologic omalizumab in severe asthma in adults: Results of the SoMOSA study. Am. J. Respir. Crit. Care Med. 2024 Aug 1;210(3):288–297. 10.1164/rccm.202310-1730OC
15 Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: A 20-year follow-up cohort study of 42,875 US Adults. J. Clin. Med. 2023 Jan 31;12(3):1128. 10.3390/jcm12031128
16 Qi Q, Zhuang L, Shen Y, Geng Y, Yu S, Chen H, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016 Jul 15;122(14):2158–67. 10.1002/cncr.30057
17 Liang Z, Liu L, Zhao H, Xia Y, Zhang W, Ye Y, et al. A systemic inflammatory endotype of asthma with more severe disease identified by unbiased clustering of the serum cytokine profile. Medicine (Baltimore). 2016 Jun;95(25):e3774. 10.1097/MD.0000000000003774
18 Monteseirín J. Neutrophils and asthma. J. Investig. Allergol. Clin. Immunol. 2009; 19:340–54.
19 Soehnlein O, Weber C, Lindbom L. Neutrophil granule proteins tune monocytic cell function. Trends Immunol. 2009;30:538–46. 10.1016/j.it.2009.06.006
20 Sur S, Crotty TB, Kephart GM, Hyma BA, Colby TV, Reed CE, et al. Sudden-onset fatal asthma. A distinct entity with few eosinophils and relatively more neutrophils in the airway submucosa? Am. Rev. Respir. Dis. 1993 Sep 148(3):713–9. 10.1164/ajrccm/148.3.713
21 Gane JM, Stockley RA, Sapey E. TNF-α autocrine feedback loops in human monocytes: The pro-and anti-inflammatory roles of the TNF-α receptors support the concept of selective TNFR1 blockade in vivo. J. Immunol. Res. 2016;1079851. 10.1155/2016/1079851
22 Eguíluz-Gracia I, Malmstrom K, Dheyauldeen SA, Lohi J, Sajantila A, Aaløkken R, et al. Monocytes accumulate in the airways of children with fatal asthma. Clin. Exp. Allergy. 2018; 48:1631–9. 10.1111/cea.13265
23 Schuijs MJ, Willart MA, Hammad H, Lambrecht BN. Cytokine targets in airway inflammation. Curr Opin Pharmacol. 2013;13:351–61. 10.1016/j.coph.2013.03.013
24 Olcay I, Yardımcı S, Delibaşı T, Müftüoğlu O. Platelet functions in patients with allergic asthma. Turk. J. Haematol. 2001 Dec 5;18(4):245–50.
25 Corlateanu A, Stratan I, Covantev S, Botnaru V, Corlateanu O, Siafakas N. Asthma and stroke: A narrative review. Asthma. Res. Pract. 2021;7:3. 10.1186/s40733-021-00069-x
26 Mizuno M, Adachi M, Maruyama S, Suganuma T, Okada T, Takahashi T. The changes in plasma beta-thromboglobulin (Beta-TG), platelet factor 4 (PF4) and thromboxane B2 (TXB2) after a bronchial provocation test (BPT) with house dust (HD) allergen. Arerugi. 1991;40(5):500–5.
27 Idzko M, Pitchford S, Page C. Role of platelets in allergic airway inflammation. J. Allergy Clin. Immunol. 2015;135(6):1416–23. 10.1016/j.jaci.2015.04.028
28 Cheng W, Bu X, Xu C, Wen G, Kong F, Pan H, et al. Higher systemic immune-inflammation index and systemic inflammation response index levels are associated with stroke prevalence in the asthmatic population: A cross-sectional analysis of the NHANES 1999-2018. Front. Immunol. 2023 Aug 4;14:1191130. 10.3389/fimmu.2023.1191130
29 Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15:e493–e503. 10.1016/S1470-2045(14)70263-3
30 Erdogan T. Role of systemic immune-inflammation index in asthma and NSAID-exacerbated respiratory disease. Clin. Respir. J. 2021;15:400–5. 10.1111/crj.13314
31 Tarkowski B, Ławniczak J, Tomaszewska K, Kurowski M, Zalewska-Janowska A. Chronic urticaria treatment with omalizumab-verification of NLR, PLR, SIRI and SII as biomarkers and predictors of treatment efficacy. J. Clin. Med. 2023 Apr 1;12(7):2639. 10.3390/jcm12072639